Alkermes plc Ordinary Shares Preferred Shares Debt Securities Form of Underwriting AgreementAlkermes Plc. • November 12th, 2013 • Pharmaceutical preparations • New York
Alkermes plc (the “Company”), a company incorporated under the laws of Ireland, proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ ] ordinary shares, par value $0.01 per share (the “Ordinary Shares”) and/or [ ] preferred shares, par value $0.01 per share (the “Preferred Shares”) and/or $[ ] principal amount of debt securities (the “Debt Securities” and, collectively with the Ordinary Shares and the Preferred Shares, the “Securities”) of the Company. To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. The use of the neuter in this Agreement shall include the feminine and masculine wherever appropriate. Certain terms used herein are defined in Section 22 here
INDENTURE Dated as of [Date] Between ALKERMES PLC, as Company and [TRUSTEE], as Trustee DEBT SECURITIESIndenture • November 12th, 2013 • Alkermes Plc. • Pharmaceutical preparations • New York
INDENTURE dated as of [Date], between ALKERMES PLC, a corporation incorporated under the laws of the Republic of Ireland (the “Company”), and [TRUSTEE], a [national banking association], as trustee (the “Trustee”).
AMENDMENT NO. 7 TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • July 26th, 2023 • Alkermes Plc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED CREDIT AGREEMENT, dated as of September 16, 2011, as amended and restated on September 25, 2012, as amended by the Second Amendment on February 14, 2013, as further amended by the Third Amendment on May 22, 2013, as further amended by the Fourth Amendment on October 12, 2016, as further amended by the Fifth Amendment on March 26, 2018, and as further amended by the Sixth Amendment on March 12, 2021, and as further amended by the Seventh Amendment on June 28, 2023, among ALKERMES, INC., a corporation organized under the laws of the Commonwealth of Pennsylvania (the “Borrower”), ALKERMES PLC, a company incorporated under the laws of the Republic of Ireland (registered number 498284) (“Holdings”), ALKERMES PHARMA IRELAND LIMITED, a private limited company organized under the laws of the Republic of Ireland (registered number 448848) and a wholly owned indirect subsidiary of Holdings (the “Intermediate Holdco”) and ALKERMES US HOLDINGS, INC., a Delaware corporatio
Date: 26, September 2003 ELAN CORPORATION, PLC. AND ACORDA THERAPEUTICS, INC. SUPPLY AGREEMENTSupply Agreement • October 25th, 2023 • Alkermes Plc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • November 2nd, 2016 • Alkermes Plc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made as of the ____ day of DATE 20__ between Alkermes, Inc., a Pennsylvania corporation (the “Company”), and NAME of __________, _________ (“Executive”).
SEPARATION AGREEMENT by and between Alkermes PLC and MURAL ONCOLOGY PLC Dated as of November 13, 2023Separation Agreement • November 15th, 2023 • Alkermes Plc. • Pharmaceutical preparations • Delaware
This SEPARATION AGREEMENT (this “Agreement”), dated as of November 13, 2023, is entered into by and between Alkermes plc, an Irish public limited company (“Alkermes”), Mural Oncology plc, an Irish public limited company (“Mural”), and, solely with respect to Article II, Section 4.5 and Section 7.12, Mural Oncology, Inc., a Delaware corporation (“Mural US”). “Party” or “Parties” means Alkermes, Mural or Mural US, individually or collectively, as the case may be. Each capitalized term used and not elsewhere defined herein has the meaning set forth in Section 1.1.
Alkermes plc Ordinary Shares ($0.01 par value) Form of Underwriting AgreementAlkermes Plc. • February 29th, 2012 • Pharmaceutical preparations • New York
Elan Science Three Limited (the “Selling Shareholder”), a company incorporated under the laws of Ireland, proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, ordinary shares, $0.01 par value (“Ordinary Shares”) of Alkermes plc, a company incorporated under the laws of Ireland (the “Company”) (said shares to be sold by the Selling Shareholder being hereinafter called the “Underwritten Securities”). The Selling Shareholder also proposes to grant to the Underwriters an option to purchase up to additional Ordinary Shares (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the s
AMENDMENT NO. 6 TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • April 28th, 2021 • Alkermes Plc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED CREDIT AGREEMENT, dated as of September 16, 2011, as amended and restated on September 25, 2012, as amended by the Second Amendment on February 14, 2013, as further amended by the Third Amendment on May 22, 2013, as further amended by the Fourth Amendment on October 12, 2016 and, as further amended by the Fifth Amendment on March 26, 2018, and as further amended by the Sixth Amendment on March 12, 2021, among ALKERMES, INC., a corporation organized under the laws of the Commonwealth of Pennsylvania (the “Borrower”), ALKERMES PLC, a company incorporated under the laws of the Republic of Ireland (registered number 498284) (“Holdings”), ALKERMES PHARMA IRELAND LIMITED, a private limited company organized under the laws of the Republic of Ireland (registered number 448848) and a wholly owned indirect subsidiary of Holdings (the “Intermediate Holdco”) and ALKERMES US HOLDINGS, INC., a Delaware corporation and a wholly owned subsidiary of Intermediate Holdco (“Holdc
THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • April 26th, 2018 • Alkermes Plc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the “Third Amendment”) is entered into effective as of March 20, 2018, (the “Third Amendment Effective Date”) between AMYLIN PHARMACEUTICALS, LLC, a Delaware limited liability corporation having a principal place of business at 9360 Towne Centre Drive, San Diego, CA 92121 (“Amylin”), and ALKERMES PHARMA IRELAND LIMITED, a private limited company incorporated in Ireland (registered number 448848) having a registered address at Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”) who is the successor-in-interest to ALKERMES CONTROLLED THERAPEUTICS INC. II (“ACTII”). Amylin and APIL are referred to herein collectively as “Parties” and individually as a “Party”.
ALKERMES PLCAlkermes PLC • September 20th, 2011 • Alkermes Plc. • Pharmaceutical preparations
This Deed of Indemnification (“Deed”) is made as of 2011 by and between Alkermes plc, a public limited company incorporated in Ireland (registered number 498284) having its registered office at Treasury Building, Grand Canal Street, Lower, Dublin 2 (the “Company”) and (“Indemnitee”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • July 30th, 2015 • Alkermes Plc. • Pharmaceutical preparations
WHEREAS, Alkermes, Inc., a Pennsylvania corporation (the “Company”) and Mark P. Stejbach of Concord, MA (“Executive”) have previously entered into an Employment Agreement dated as of February 29, 2012 (the “Agreement”); and
PURCHASE AND SALE AGREEMENT by and among ALKERMES PHARMA IRELAND LIMITED, DARAVITA LIMITED, EAGLE HOLDINGS USA, INC., RECRO PHARMA, INC. and RECRO PHARMA LLCPurchase and Sale Agreement • April 16th, 2015 • Alkermes Plc. • Pharmaceutical preparations • Delaware
This PURCHASE AND SALE AGREEMENT (this “Agreement”), dated as of March 7, 2015, is by and among Alkermes Pharma Ireland Limited, a private limited company incorporated in Ireland (“APIL”), Daravita Limited, a private limited company incorporated in Ireland (“Daravita”), Eagle Holdings USA, Inc., a Delaware corporation (“Eagle Holdings”, and together with APIL, “Sellers”), Recro Pharma, Inc., a Pennsylvania corporation (“Recro”) and Recro Pharma LLC, a Delaware limited liability company and wholly-owned subsidiary of Recro (“Acquisition Sub,” and together with Recro, “Purchasers”).
TRANSITION SERVICES AGREEMENT by and between MURAL ONCOLOGY, INC. and ALKERMES, INC. Dated as of November 13, 2023Transition Services Agreement • November 15th, 2023 • Alkermes Plc. • Pharmaceutical preparations • Delaware
This TRANSITION SERVICES AGREEMENT (this “Agreement”), dated as of November 13, 2023 (the “Effective Date”), is entered into by and between Mural Oncology, Inc., a Delaware corporation and, following the Separation, a wholly owned direct subsidiary of Mural Oncology plc (“Mural US”), and Alkermes, Inc., a Pennsylvania corporation and wholly owned direct subsidiary of Alkermes plc (“Alkermes US”). “Party” or “Parties” means Mural US or Alkermes US, individually or collectively, as the case may be.
AGREEMENT AND PLAN OF MERGER BY AND AMONG ALKERMES, INC., THINKER MERGER SUB, INC., ALKERMES PLC, RODIN THERAPEUTICS, INC. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS COMPANY EQUITYHOLDER REPRESENTATIVE Dated as of November 14, 2019Agreement and Plan of Merger • November 25th, 2019 • Alkermes Plc. • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of November 14, 2019 by and among Alkermes, Inc., a Pennsylvania corporation (the “Buyer”), Thinker Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Buyer (“Merger Sub”), Rodin Therapeutics, Inc., a Delaware corporation (the “Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative, agent and attorney-in-fact of the Company Equityholders (the “Company Equityholder Representative”), and, solely for purposes of being bound by Section 10.16, Alkermes plc, an Irish company (“Parent”).
AMENDMENT TO FIRST LIEN CREDIT AGREEMENTFirst Lien Credit Agreement • September 25th, 2012 • Alkermes Plc. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED CREDIT AGREEMENT, dated as of September 16, 2011, as amended and restated on September 25, 2012, among ALKERMES, INC., a corporation organized under the laws of the Commonwealth of Pennsylvania (the “Borrower”), ALKERMES PLC, a company incorporated under the laws of the Republic of Ireland (registered number 498284) (“Holdings”), ALKERMES PHARMA IRELAND LIMITED, a private limited company organized under the laws of the Republic of Ireland (registered number 448848) and a wholly owned indirect subsidiary of Holdings (the “Intermediate Holdco”) and ALKERMES US HOLDINGS, INC., a Delaware corporation and a wholly owned subsidiary of Intermediate Holdco (“Holdco”), the several banks and other financial institutions or entities from time to time parties to this Agreement as “Lenders”, MORGAN STANLEY SENIOR FUNDING, INC. (“MSSF”), as administrative agent (in such capacity, and together with its successors and assigns in such capacity, the “Administrative Agent”), MOR
Portions of this exhibit (indicated by “[**]”) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. Schedules and similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. THIRD AMENDMENT TO...Development and License Agreement • February 21st, 2024 • Alkermes Plc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (the “Third Amendment”) is entered into effective as of March 20, 2018, (the “Third Amendment Effective Date”) between AMYLIN PHARMACEUTICALS, LLC, a Delaware limited liability corporation having a principal place of business at 9360 Towne Centre Drive, San Diego, CA 92121 (“Amylin”), and ALKERMES PHARMA IRELAND LIMITED, a private limited company incorporated in Ireland (registered number 448848) having a registered address at Connaught House, 1 Burlington Road, Dublin 4, Ireland (“APIL”) who is the successor-in-interest to ALKERMES CONTROLLED THERAPEUTICS INC. II (“ACTII”). Amylin and APIL are referred to herein collectively as “Parties” and individually as a “Party”.
THIRD AMENDMENT TO LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • February 13th, 2020 • Alkermes Plc. • Pharmaceutical preparations • New York
THIS THIRD AMENDMENT (the “Amendment”) is made and entered into as of October 30, 2019 (the “Amendment Effective Date”) to amend that certain License and Collaboration Agreement dated November 27, 2017, as amended (the “Agreement”), by and between ALKERMES PHARMA IRELAND LIMITED (“Alkermes”) and BIOGEN SWISS MANUFACTURING GMBH (“Biogen”). Unless explicitly noted otherwise, capitalized terms used but not defined herein shall have the meanings set forth in the Agreement.
Second Amendment to LeaseSecond Amendment to Lease • July 25th, 2019 • Alkermes Plc. • Pharmaceutical preparations
This Second Amendment to Lease (this “Amendment”) is by and between PDM 900 Unit, LLC, a Delaware limited liability company (“Landlord”), and Alkermes, Inc., a Pennsylvania corporation (“Tenant”), and is executed as of this 10th day of May, 2019.
March 8, 2012Alkermes Plc. • March 8th, 2012 • Pharmaceutical preparations
Reference is made to the Shareholder’s Agreement dated as of September 16, 2011 (the “Shareholder’s Agreement”), by and among Alkermes plc, a public limited company incorporated in Ireland (registered number 498284), whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland (“Alkermes”), Elan Corporation, plc, a public limited company incorporated in Ireland (registered number 30356), whose registered address is Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (the “Shareholder Parent”), and Elan Science Three Limited, a private limited company incorporated in Ireland (registered number 477401) and a wholly-owned subsidiary of the Shareholder Parent, whose registered address is Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (the “Shareholder,” together with the Shareholder Parent and Alkermes, the “Parties”). Unless specified otherwise, defined terms in this waiver and consent letter shall have the meaning assigned to them in the Sh
SEPARATION AGREEMENTSeparation Agreement • February 25th, 2016 • Alkermes Plc. • Pharmaceutical preparations • Massachusetts
This Separation Agreement (the “Separation Agreement”) is made between Rebecca J. Peterson (“Executive”) and Alkermes, Inc. (the “Company,” together with Executive, the “Parties”).
EMPLOYEE MATTERS AGREEMENT by and between ALKERMES PLC and MURAL ONCOLOGY PLC Dated as of November 13, 2023Employee Matters Agreement • November 15th, 2023 • Alkermes Plc. • Pharmaceutical preparations • Delaware
This EMPLOYEE MATTERS AGREEMENT (this “Agreement”), dated as of November 13, 2023, is entered into by and between Alkermes plc (“Alkermes”), an Irish public limited company, and Mural Oncology plc (“Mural”), an Irish public limited company. “Party” or “Parties” means Alkermes or Mural, individually or collectively, as the case may be.
ContractLicense Agreement • April 26th, 2023 • Alkermes Plc. • Pharmaceutical preparations • New Jersey
In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by “[**]”) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.
Alkermes Controlled Therapeutics Inc. II Cambridge, MA 02139 USAAnd Supply Agreement • February 25th, 2016 • Alkermes Plc. • Pharmaceutical preparations
Pursuant to that certain Manufacturing and Supply Agreement (the “Agreement”), dated August 6, 1997, among Alkermes Controlled Therapeutics Inc. II (“ACT II”), JPI Pharmaceutica International, a division of Cilag AG International Zug, a company organized under the laws of Switzerland (“JPI”), and Janssen Pharmaceutica Inc. (“Janssen US”) (JPI and Janssen US collectively referred to herein as “Janssen”), as supplemented by that certain Addendum to Manufacturing and Supply Agreement (the “Addendum”), dated August 1, 2001, among ACT II, JPI and Janssen, certain exhibits referred to in the Agreement would be agreed to by the parties in the future. Those exhibits are Exhibits A, B, E, F, G and H. This letter sets forth the agreement by the parties as to such Exhibits.
MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • February 25th, 2016 • Alkermes Plc. • Pharmaceutical preparations
JPI PHARMACEUTICA INTERNATIONAL, a division of Cilag AG International Zug, a company duly organized and existing under the laws of Switzerland, having its principal office in CH-6300 Zug, Kollerstrasse 38, Switzerland (hereinafter referred to as "JPI")
Re: Amendment to License and Collaboration AgreementAlkermes Plc. • April 25th, 2019 • Pharmaceutical preparations
We refer to the License and Collaboration Agreement dated 27 November 2017 between Alkermes Pharma Ireland Limited (“Alkermes”) and Biogen Swiss Manufacturing GmBH (“Biogen”) (the “License”). This letter is supplemental to the License and amends Section 5.1.2 thereto as set out below.
ContractDevelopment and Supplemental Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations • New York
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
FOURTH AMENDMENT TO LEASELease • July 30th, 2015 • Alkermes Plc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of December 30, 2014, by and between GI TC 850 WINTER STREET, LLC, a Delaware limited liability company (“Landlord”), and ALKERMES, INC., a Pennsylvania corporation (“Tenant”).
SECOND LIEN TERM LOAN CREDIT AGREEMENT among ALKERMES, INC., as Borrower, ALKERMES PLC as Holdings, ALKERMES PHARMA IRELAND LIMITED, as Intermediate Holdco, ALKERMES US HOLDINGS, INC., as Holdco, The Several Lenders from Time to Time Parties Hereto,...Term Loan Credit Agreement • September 16th, 2011 • Alkermes Plc. • Pharmaceutical preparations • New York
THIS SECOND LIEN TERM LOAN CREDIT AGREEMENT, dated as of September 16, 2011, among ALKERMES, INC., a corporation organized under the laws of the Commonwealth of Pennsylvania (the “Borrower”), ALKERMES PLC, a company incorporated under the laws of the Republic of Ireland (registered number 498284) (“Holdings”), ALKERMES PHARMA IRELAND LIMITED, a private limited company organized under the laws of the Republic of Ireland (registered number 448848) and a wholly owned indirect subsidiary of Holdings (the “Intermediate Holdco”) and ALKERMES US HOLDINGS, INC., a Delaware corporation and a wholly owned subsidiary of Intermediate Holdco (“Holdco”), the several banks and other financial institutions or entities from time to time parties to this Agreement as “Lenders”, MORGAN STANLEY SENIOR FUNDING, INC., as administrative agent (in such capacity, and together with its successors and assigns in such capacity, the “Administrative Agent”), MORGAN STANLEY SENIOR FUNDING, INC. and HSBC SECURITIES (U
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • July 30th, 2015 • Alkermes Plc. • Pharmaceutical preparations
WHEREAS, Alkermes, Inc., a Pennsylvania corporation (the “Company”) and Iain Brown of Alkermes, Inc. (“Vice President”) have previously entered into an Employment Agreement dated as of the 30th day of September, 2008 (the “Agreement”); and
March 8, 2012Alkermes Plc. • May 18th, 2012 • Pharmaceutical preparations
Reference is made to the Shareholder’s Agreement dated as of September 16, 2011 (the “Shareholder’s Agreement”), by and among Alkermes plc, a public limited company incorporated in Ireland (registered number 498284), whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland (“Alkermes”), Elan Corporation, plc, a public limited company incorporated in Ireland (registered number 30356), whose registered address is Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (the “Shareholder Parent”), and Elan Science Three Limited, a private limited company incorporated in Ireland (registered number 477401) and a wholly-owned subsidiary of the Shareholder Parent, whose registered address is Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (the “Shareholder,” together with the Shareholder Parent and Alkermes, the “Parties”). Unless specified otherwise, defined terms in this waiver and consent letter shall have the meaning assigned to them in the Sh
ContractLicense Agreement • May 23rd, 2013 • Alkermes Plc. • Pharmaceutical preparations • New Jersey
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
LICENSE AGREEMENTLicense Agreement • February 25th, 2016 • Alkermes Plc. • Pharmaceutical preparations
This Agreement is made as of the 13 day February of 1996, between MEDISORB TECHNOLOGIES INTERNATIONAL L.P., a Delaware limited partnership (hereinafter "Medisorb") and JANSSEN PHARMACEUTICA INC., a New Jersey corporation ("Janssen US").
ADDENDUM TO MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • February 25th, 2016 • Alkermes Plc. • Pharmaceutical preparations
This Addendum to Manufacturing and Supply Agreement (this “Addendum”), dated as of the 1 day of August, 2001 (the “Effective Date”) is by and between JPI PHARMACEUTICA INTERNATIONAL, a division of Cilag AG International Zug, a company duly organized and existing under the laws of Switzerland, having its principal office in CH- 6300 Zug, Kollerstrasse 38, Switzerland (“JPI”) and JANSSEN PHARMACEUTICA Inc., 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA (“Janssen US” and, together with JPI, “Janssen”) on the one hand and Alkermes Controlled Therapeutics Inc. II, a company organized and existing under the laws of the Commonwealth of Pennsylvania, having its principal office at 64 Sidney Street, Cambridge MA 02139-4136, USA (“ACTII”) on the other hand.
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ADDENDUM TO MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • July 30th, 2015 • Alkermes Plc. • Pharmaceutical preparations
This Addendum to Manufacturing and Supply Agreement (this "Addendum"), dated as of the 1st day of August, 2001 (the "Effective Date") is by and between JPI PHARMACEUTICA INTERNATIONAL, a division of Cilag AG International Zug, a company duly organized and existing under the laws of\ Switzerland, having its principal office in CH-6300 Zug, Kollerstrasse 38, Switzerland ("JPI") and JANSSEN PHARMACEUTICA Inc., 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA ("Janssen US" and, together with JPI, "Janssen") on the one hand and Alkermes Controlled Therapeutics Inc. II, a company organized and existing under the laws of the Commonwealth of Pennsylvania, having its principal office at 64 Sidney Street, Cambridge MA 02139-4136, USA ("ACTII") on the other hand.
ContractAlkermes Plc. • May 23rd, 2013 • Pharmaceutical preparations
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
